Literature DB >> 19219927

Incidence and impact of adverse effects to antibiotics in hospitalized adults with pneumonia.

Robert Y Lin1, Farzana Nuruzzaman, Shaili N Shah.   

Abstract

BACKGROUND: This study sought to define the incidence, economic impact, and nature of adverse drug effects (ADEs) related to antibiotics in pneumonia hospitalizations in the US.
METHODS: Adult pneumonia hospitalizations were tabulated in statewide (New York) and national databases, respectively, from 2000 through 2005. The incidences of antibiotic related ADEs were determined by identifying antibiotic specific e-codes (external cause of injury codes). The modeled effect of the presence of antibiotic ADEs on length of stay (LOS) and total charges were also calculated. ADEs due to specific antibiotic classes, and the presence of certain cutaneous allergic and gastro-intestinal manifestations commonly attributable to ADEs, were tabulated.
RESULTS: ADEs related to antibiotics were reported in a small but consistent proportion (0.45-0.6%) of pneumonia hospitalizations in both cohorts. The most common identifiable antibiotics class associated with ADEs was the cephalosporins followed by penicillins and quinolones. Over 60% of the ADEs were associated with reported dermal/allergic and gastro-intestinal manifestations. Multivariate analysis adjusting for co-morbid conditions and demographic factors showed that the presence of an antibiotic adverse drug effect was a significant independent predictor of greater LOS and higher total hospital charges.
CONCLUSIONS: ADEs related to antibiotics can be identified by analyzing administrative hospitalization databases. For pneumonia, a common hospitalization diagnosis, there is a defined calculable impact and incidence of antibiotic associated adverse effects. This should be considered in planning hospitalization resource allocation and in developing equitable hospitalization reimbursements. Identifying the nature of antibiotic associated adverse effects may facilitate the development of strategies for reducing these adverse effects.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19219927     DOI: 10.1002/jhm.414

Source DB:  PubMed          Journal:  J Hosp Med        ISSN: 1553-5592            Impact factor:   2.960


  7 in total

1.  Association of Adverse Events With Antibiotic Use in Hospitalized Patients.

Authors:  Pranita D Tamma; Edina Avdic; David X Li; Kathryn Dzintars; Sara E Cosgrove
Journal:  JAMA Intern Med       Date:  2017-09-01       Impact factor: 21.873

2.  An explainable machine learning platform for pyrazinamide resistance prediction and genetic feature identification of Mycobacterium tuberculosis.

Authors:  Andrew Zhang; Ling Teng; Gil Alterovitz
Journal:  J Am Med Inform Assoc       Date:  2021-03-01       Impact factor: 4.497

3.  Heterogeneous models for an early discrimination between sepsis and non-infective SIRS in medical ward patients: a pilot study.

Authors:  Filippo Mearelli; Nicola Fiotti; Nicola Altamura; Michela Zanetti; Giovanni Fernandes; Ismet Burekovic; Alessandro Occhipinti; Daniele Orso; Carlo Giansante; Chiara Casarsa; Gianni Biolo
Journal:  Intern Emerg Med       Date:  2013-12-22       Impact factor: 3.397

4.  Oral versus intravenous clarithromycin in moderate to severe community-acquired pneumonia: an observational study.

Authors:  Nikolas Rae; Aran Singanayagam; Stuart Schembri; James D Chalmers
Journal:  Pneumonia (Nathan)       Date:  2017-02-05

5.  Causality and preventability assessment of adverse drug reactions and adverse drug events of antibiotics among hospitalized patients: A multicenter, cross-sectional study in Lahore, Pakistan.

Authors:  Sadia Iftikhar; Muhammad Rehan Sarwar; Anum Saqib; Muhammad Sarfraz
Journal:  PLoS One       Date:  2018-06-27       Impact factor: 3.240

6.  Association of Adverse Drug Events with Broad-spectrum Antibiotic Use in Hospitalized Patients: A Single-center Study.

Authors:  Hideharu Hagiya; Ryohei Kokado; Akiko Ueda; Hideo Okuno; Daiichi Morii; Shigeto Hamaguchi; Norihisa Yamamoto; Hisao Yoshida; Kazunori Tomono
Journal:  Intern Med       Date:  2019-05-22       Impact factor: 1.271

7.  Vital signs: improving antibiotic use among hospitalized patients.

Authors:  Scott Fridkin; James Baggs; Ryan Fagan; Shelley Magill; Lori A Pollack; Paul Malpiedi; Rachel Slayton; Karim Khader; Michael A Rubin; Makoto Jones; Matthew H Samore; Ghinwa Dumyati; Elizabeth Dodds-Ashley; James Meek; Kimberly Yousey-Hindes; John Jernigan; Nadine Shehab; Rosa Herrera; Clifford L McDonald; Amy Schneider; Arjun Srinivasan
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2014-03-07       Impact factor: 17.586

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.